Company |
Stock Price 12/31/00 |
Stock Price 12/31/01 |
Stock Price Change(%) |
Shares Out (M)* |
Mkt. Cap. (M)** |
3-Dimensional Pharmaceuticals Inc. (Nasdaq:DDDP) |
14.8125 |
8.4900 |
-42.7 |
22.0 |
186.7 |
Aclara BioSciences Inc. (Nasdaq:ACLA) |
10.8750 |
5.0700 |
-53.4 |
35.8 |
181.4 |
Affymetrix Inc. (Nasdaq:AFFX) |
74.4375 |
37.7500 |
-49.3 |
57.9 |
2,187.2 |
Agilent Technologies Inc. (NYSE:A) | 54.7500 |
28.5100 |
-47.9 |
460.6 |
13,132.8 |
Applied Molecular Evolution Inc. (Nasdaq:AMEV) | 17.0625 |
12.3100 |
-27.9 |
23.6 |
290.5 |
Ariad Pharmaceuticals Inc.1 (Nasdaq:ARIA) |
4.7500 |
5.3300 |
12.2 |
30.2 |
160.9 |
Array BioPharma Inc. (Nasdaq:ARRY) |
8.9375 |
14.8600 |
66.3 |
23.5 |
349.1 |
Bruker Daltonics Inc. (Nasdaq:BDAL) |
23.5625 |
16.3500 |
-30.6 |
54.9 |
897.2 |
Celera Genomics Group (NYSE:CRA) |
36.1250 |
26.6900 |
-26.1 |
62.2 |
1,659.4 |
Ciphergen Biosystems Inc. (Nasdaq:CIPH) |
13.2500 |
8.0000 |
-39.6 |
27.0 |
215.6 |
Commonweatlh Biotechnologies Inc. (Nasdaq:CBTE) |
3.7500 |
2.7200 |
-27.5 |
2.1 |
5.6 |
Compugen Ltd. (Nasdaq:CGEN) |
6.2500 |
4.7000 |
-24.8 |
26.0 |
122.2 |
CuraGen Corp. (Nasdaq:CRGN) |
27.3125 |
22.3700 |
-18.1 |
48.7 |
1,089.3 |
CytoGenix Inc. (OTC BB:CYGX) |
0.1250 |
0.1950 |
56.0 |
41.7 |
8.1 |
DeCode genetics Inc. (Nasdaq:DCGN) |
10.5000 |
9.8000 |
-6.7 |
45.2 |
442.7 |
Deltagen Inc. (Nasdaq:DGEN) |
10.4375 |
9.2000 |
-11.9 |
32.1 |
295.1 |
Discovery Partners International Inc. (Nasdaq:DPII) |
12.1250 |
7.4000 |
-39.0 |
24.2 |
179.2 |
Diversa Corp. (Nasdaq:DVSA) |
17.9375 |
14.1500 |
-21.1 |
35.5 |
501.7 |
DNAPrint genomics Inc. (Nasdaq:DNAP) |
0.1094 |
0.0500 |
-54.3 |
413.3 |
20.7 |
Exact Sciences Corp.2 (Nasdaq:EXAS) |
14.0000 |
10.2600 |
-26.7 |
18.8 |
192.7 |
Exelixis Pharmaceuticals Inc. (Nasdaq:EXEL) |
14.6250 |
16.6200 |
13.6 |
49.5 |
822.9 |
Genaera Corp. (Nasdaq:GENR) |
2.2188 |
3.9000 |
75.8 |
32.9 |
128.2 |
Genaissance Pharmaceuticals Inc. (Nasdaq:GNSC) |
18.0000 |
4.6500 |
-74.2 |
22.8 |
105.9 |
Gene Logic Inc. (Nasdaq:GLGC) |
18.3750 |
18.8400 | 2.5 |
26.7 |
503.7 |
Genencor International Inc. (Nasdaq:GCOR) |
18.0000 |
15.9600 |
-11.3 |
59.9 |
956.4 |
Genome Therapeutics Corp. (Nasdaq:GENE) |
6.9688 |
6.8100 |
-2.3 |
22.8 |
155.0 |
Genomic Solutions Inc. (Nasdaq:GNSL) |
7.6250 |
2.4000 |
-68.5 |
24.3 |
58.4 |
Genomica Corp. (Nasdaq:GNOM) |
5.2810 |
4.5600 |
-13.7 |
23.0 |
104.9 |
Genset SA3 (Nasdaq:GENXY; Nouveau Marche: GENSET) |
12.6250 |
2.6700 |
-78.9 |
8.1 |
21.6 |
Genzyme Molecular Oncology (Nasdaq:GZMO) |
9.1875 |
8.0000 |
-12.9 |
16.7 |
133.8 |
Human Genome Sciences Inc. (Nasdaq:HGSI) |
69.3125 |
33.7200 |
-51.4 |
127.8 |
4,309.5 |
Hyseq Inc. (Nasdaq:HYSQ) |
14.3750 |
7.7200 |
-46.3 |
19.1 |
147.5 |
ID Biomedical Corp. (Nasdaq:IDBE; TSE:IDB) |
4.8750 |
4.3000 |
-11.8 |
30.0 |
129.1 |
Incyte Genomics Inc. (Nasdaq:INCY) |
24.8750 |
19.4400 |
-21.8 |
66.4 |
1,290.9 |
InforMax Inc. (Nasdaq:INMX) |
10.3750 |
2.9500 |
-71.6 |
24.3 |
71.8 |
Invitrogen Corp. (Nasdaq:IVGN) |
86.3750 |
61.9300 |
-28.3 |
53.0 |
3,279.9 |
Large Scale Biology Corp. (Nasdaq:LSBC) |
9.5000 |
4.5000 |
-52.6 |
24.6 |
110.6 |
Lexicon Genetics Inc. (Nasdaq:LEXG) |
16.6250 |
11.5400 |
-30.6 |
51.9 |
599.1 |
LION Bioscience AG (Nasdaq:LEON; Neur Markt:LIO) |
75.3750 |
16.2500 |
-78.4 |
18.8 |
304.8 |
Lynx Therapeutics Inc. (Nasdaq:LYNX) |
9.0000 |
4.0300 |
-55.2 |
13.8 |
55.5 |
Maxygen Inc. (Nasdaq:MAXY) |
24.5000 |
17.5700 |
-28.3 |
33.9 |
596.4 |
MediChem LifeSciences Inc. (Nasdaq:MCLS) |
4.6250 |
1.4500 |
-68.6 |
26.6 |
38.6 |
Millennium Pharmaceuticals Inc. (Nasdaq:MLNM) |
61.8750 |
24.5100 |
-60.4 |
221.4 |
5,425.5 |
Myriad Genetics Inc. (Nasdaq:MYGN) |
82.7500 |
52.6400 |
-36.4 |
23.5 |
1,239.4 |
Nanogen Inc. (Nasdaq:NGEN) |
9.0000 |
5.7700 |
-35.9 |
21.6 |
124.4 |
NaPro Biotherapeutics Inc. (Nasdaq:NPRO) |
8.4844 |
11.4000 |
34.4 |
28.2 |
321.9 |
Onyx Pharmaceuticals Inc. (Nasdaq:ONXX) |
14.8750 |
5.1200 |
-65.6 |
18.5 |
94.8 |
Orchid Biosciences Inc. (Nasdaq:ORCH) |
14.0000 |
5.5000 |
-60.7 |
39.5 |
217.5 |
Oxford Glycosciences plc (Nasdaq:OGSI; LSE:OGS) |
21.2500 |
9.7000 |
-54.4 |
N/A |
N/A |
Paradigm Genetics Inc.4 (Nasdaq:PDGM) |
10.0000 |
5.7000 |
-43.0 |
31.4 |
179.2 |
Regeneron Pharmaceuticals Inc. (Nasdaq:REGN) |
35.2656 |
28.1600 |
-20.1 |
41.2 |
1,159.2 |
Rigel Pharmaceuticals Inc. (Nasdaq:RIGL) |
10.0000 |
4.6500 |
-53.5 |
37.6 |
174.8 |
Sangamo BioSciences Inc. (Nasdaq:SGMO) |
19.5000 |
9.3400 |
-52.1 |
24.4 |
228.3 |
Sequenom Inc. (Nasdaq:SQNM) |
14.0000 | 10.6700 |
-23.8 |
37.4 |
398.6 |
SignalGene Inc.5 (TSE:SGI) |
C$0.8 |
C$0.39 |
-51.3 |
121.9 |
C$47.6 |
SYN X Pharma Inc.6 (TSE:SYY) |
N/A |
C$7.75 |
N/A |
10.1 |
C$78.2 |
Synaptic Pharmaceutical Corp. (Nasdaq:SNAP) |
5.1250 |
6.0200 |
17.5 |
10.9 |
65.9 |
Tm Bioscience Corp. (CDNX:TMC) |
C$0.46 |
C$0.39 |
-15.2 |
99.9 |
C$39.0 |
Transgenomic Inc. (Nasdaq:TBIO) |
10.5000 |
11.0000 |
4.8 |
23.2 |
255.7 |
Variagenics Inc. (Nasdaq:VGNX) |
11.8594 |
3.0800 |
-74.0 |
23.4 |
72.0 |
ZymoGenetics Inc.7 (Nasdaq:ZGEN) |
- |
|
|
45 |
540 |
Notes: There are 68 public genomics companies profiled. The 61 companies listed in this table include only those trading on American and Canadian stock exchanges. Autogen Ltd. (ASX:AGT), Genesis Research and Development Corp. Ltd. (NZSE:GEN; ASX:GEN), GPC Biotech AG (Neuer Markt:GPC), MediGene AG (Neuer Markt:MDG), Pharmagene plc (LSE:PGN), Proteome Sciences plc (LSE:PRM) and Proteome Systems Inc. (an unlisted public company) are not included in this table. All numbers are in U.S. dollars unless otherwise noted; US$1 = C$1.59. * Shares outstanding data were compiled from corporate quarterly statements for the period ending Sept. 30, 2001, company websites and other sources. Numbers were rounded for data presentation. ** Market capitalization values, calculated by multiplying the Dec. 31, 2001, stock prices by shares outstanding, are approximate. Numbers were rounded for data presentation. N/A = Not available; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; NZSE = New Zealand Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange 1. The number of shares outstanding for Ariad Pharmaceuticals Inc. does not include the private placement in November 2001 of 1,927,712 shares of common stock. 2. Exact Sciences Corp.'s shares began trading on Jan. 31, 2001, following an IPO at $14 per share. The percentage change of -26.71 reflects the loss from the IPO price through Dec. 31, 2001. 3. The number of shares outstanding for Genset SA are ordinary shares as of Sept. 30, 2001, or 24,315,550 equivalent American depositary shares. 4. The number of shares outstanding for Paradigm Genetics Inc. includes the private placement in October 2001 of approximately 5.1 million shares of common stock. 5. The number of shares outstanding for SignalGene Inc. is as of Jan. 25, 2002. 6. The Dec. 31, 2000, stock price for SYN X Pharma Inc. was not available; SYN X traded on the Canadian Venture Exchange on that date. It began trading on the Toronto Stock Exchange on Aug. 1, 2001. 7. ZymoGenetics Inc. went public on Feb. 1, 2002, selling 10 million shares at $12 per share. Shares outstanding are as of the IPO date. |